drugset / Trial / NCT05409027

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

NCT05409027

Phase 1 Completed 12 enrolled Sparrow Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)

Timeline

Start
2021-07-23
Primary completion
2022-03-10
Completion
2024-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject clofutriben Small molecule 1 mg Oral
Subject clofutriben Small molecule 15 mg Oral
Background Cortisone-d8 Unknown 12 ug Subcutaneous